Co-Authors
This is a "connection" page, showing publications co-authored by Aimee Mcrae-Clark and Nathaniel Baker.
Connection Strength
3.805
-
Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials. Drug Alcohol Depend. 2018 06 01; 187:270-277.
Score: 0.634
-
Differential prevalence of Adverse Childhood Experiences (ACEs) by gender and substance used in individuals with cannabis, cocaine, opioid, and tobacco use disorders. Am J Drug Alcohol Abuse. 2023 Mar 07; 1-9.
Score: 0.223
-
Oxytocin moderates corticolimbic social stress reactivity in cocaine use disorder and healthy controls. Compr Psychoneuroendocrinol. 2022 Aug; 11:100150.
Score: 0.211
-
Sex and drug differences in stress, craving and cortisol response to the trier social stress task. Psychopharmacology (Berl). 2022 Sep; 239(9):2819-2827.
Score: 0.211
-
Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug Alcohol Depend. 2021 12 01; 229(Pt B):109111.
Score: 0.201
-
The effect of oxytocin, gender, and ovarian hormones on stress reactivity in individuals with cocaine use disorder. Psychopharmacology (Berl). 2020 Jul; 237(7):2031-2042.
Score: 0.183
-
Approach bias modification for cannabis use disorder: A proof-of-principle study. J Subst Abuse Treat. 2018 04; 87:16-22.
Score: 0.156
-
Impact of endogenous progesterone on reactivity to yohimbine and cocaine cues in cocaine-dependent women. Pharmacol Biochem Behav. 2018 02; 165:63-69.
Score: 0.154
-
Repetitive transcranial magnetic stimulation (rTMS) administration to heavy cannabis users. Am J Drug Alcohol Abuse. 2018; 44(1):47-55.
Score: 0.151
-
Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention. Psychiatry Res. 2017 Mar; 249:318-320.
Score: 0.146
-
Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse cannabis outcomes for women. Addict Behav. 2016 09; 60:197-202.
Score: 0.138
-
Vilazodone for cannabis dependence: A randomized, controlled pilot trial. Am J Addict. 2016 Jan; 25(1):69-75.
Score: 0.135
-
Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 2015 Nov 01; 156:29-37.
Score: 0.132
-
Concordance of Direct and Indirect Measures of Medication Adherence in A Treatment Trial for Cannabis Dependence. J Subst Abuse Treat. 2015 Oct; 57:70-4.
Score: 0.129
-
Impact of acute guanfacine administration on stress and cue reactivity in cocaine-dependent individuals. Am J Drug Alcohol Abuse. 2015 Mar; 41(2):146-52.
Score: 0.123
-
Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. Psychopharmacology (Berl). 2013 Aug; 228(4):623-31.
Score: 0.112
-
Stress- and cue-elicited craving and reactivity in marijuana-dependent individuals. Psychopharmacology (Berl). 2011 Nov; 218(1):49-58.
Score: 0.099
-
The impact of lofexidine on stress-related opioid craving and relapse: Design and methodology of a randomized clinical trial. Contemp Clin Trials. 2021 12; 111:106616.
Score: 0.051
-
Latency to cannabis dependence mediates the relationship between age at cannabis use initiation and cannabis use outcomes during treatment in men but not women. Drug Alcohol Depend. 2021 01 01; 218:108383.
Score: 0.047
-
Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology (Berl). 2020 Feb; 237(2):479-490.
Score: 0.044
-
Neural correlates of oxytocin and cue reactivity in cocaine-dependent men and women with and without childhood trauma. Psychopharmacology (Berl). 2019 Nov 07.
Score: 0.044
-
Oxytocin-Induced Changes in Intrinsic Network Connectivity in Cocaine Use Disorder: Modulation by Gender, Childhood Trauma, and Years of Use. Front Psychiatry. 2019; 10:502.
Score: 0.043
-
Methods to reduce the incidence of false negative trial results in substance use treatment research. Curr Opin Psychol. 2019 12; 30:35-41.
Score: 0.042
-
Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 2018 01 01; 182:1-7.
Score: 0.038
-
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257.
Score: 0.037
-
Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study. Am J Addict. 2017 Mar; 26(2):136-144.
Score: 0.036
-
Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence. Psychiatry Res. 2015 Sep 30; 229(1-2):94-100.
Score: 0.033
-
Yohimbine administration and cue-reactivity in cocaine-dependent individuals. Psychopharmacology (Berl). 2014 Oct; 231(21):4157-65.
Score: 0.030
-
A double blind, placebo-controlled study of the effects of post-retrieval propranolol on reconsolidation of memory for craving and cue reactivity in cocaine dependent humans. Psychopharmacology (Berl). 2013 Apr; 226(4):721-37.
Score: 0.028
-
A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012 Aug; 169(8):805-12.
Score: 0.027
-
Impaired cognitive performance in subjects with methamphetamine dependence during exposure to neutral versus methamphetamine-related cues. Am J Drug Alcohol Abuse. 2012 May; 38(3):251-9.
Score: 0.026
-
A randomized, placebo-controlled laboratory study of the effects of D-cycloserine on craving in cocaine-dependent individuals. Psychopharmacology (Berl). 2013 Apr; 226(4):739-46.
Score: 0.026
-
The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina. Am J Addict. 2011 Sep-Oct; 20(5):447-55.
Score: 0.025
-
Influence of cocaine dependence and early life stress on pituitary-adrenal axis responses to CRH and the Trier social stressor. Psychoneuroendocrinology. 2010 Nov; 35(10):1492-500.
Score: 0.023
-
Extinction of drug cue reactivity in methamphetamine-dependent individuals. Behav Res Ther. 2010 Sep; 48(9):860-5.
Score: 0.023
-
Determinants of cue-elicited craving and physiologic reactivity in methamphetamine-dependent subjects in the laboratory. Am J Drug Alcohol Abuse. 2010 Mar; 36(2):106-13.
Score: 0.023
-
Reactivity to laboratory stress provocation predicts relapse to cocaine. Drug Alcohol Depend. 2010 Jan 01; 106(1):21-7.
Score: 0.022